CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 169,065	$ 171,945
Marketable securities	433,410	192,648
Trade receivable, net	328,342	308,269
Inventory	91,281	80,608
Prepaid expenses	104,891	88,838
Other current assets	44,096	33,946
Total current assets	1,171,085	876,254
Property and equipment, net	14,534	14,690
Intangible assets, net	55,910	56,438
Other assets	130,188	129,830
Total assets	1,371,717	1,077,212
Current liabilities:
Accounts payable	56,202	51,683
Accrued expenses and other current liabilities	457,412	420,019
Current portion of mandatorily redeemable preferred shares	62,500	62,500
Total current liabilities	576,114	534,202
Long-term debt	634,106	626,720
Liability related to sale of future royalties, net	377,998	367,645
Mandatorily redeemable preferred shares, net	162,994	155,737
Derivative liability	9,120	13,110
Obligation to perform R&D services	36,016	50,571
Other long-term liabilities	41,782	12,236
Total liabilities	1,838,130	1,760,221
Commitments and contingencies
Contingently redeemable non-controlling interests	0	60,000
Shareholders’ deficit:
Common shares, no par value; 200,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 70,540,802 and 66,933,531 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively	2,112,686	1,676,792
Additional paid-in capital	129,580	169,656
Accumulated other comprehensive loss	(2,398)	(73)
Accumulated deficit	(2,702,154)	(2,585,755)
Total shareholders’ deficit attributable to Biohaven Pharmaceutical Holding Company Ltd.	(462,286)	(739,380)
Non-controlling interests in consolidated subsidiaries	(4,127)	(3,629)
Total shareholders' deficit	(466,413)	(743,009)
Total liabilities and shareholders’ deficit	$ 1,371,717	$ 1,077,212